Latest Investment News

Neurotech International reports a dramatic reduction in half-year losses alongside significant clinical and regulatory progress for its lead cannabinoid therapy NTI164. The company also strengthens its cash position through a $4 million placement and a $4.7 million R&D tax refund.

DorsaVi Limited reported a steep increase in its half-year loss to $3.6 million, driven by declining revenues and a sharp rise in operating costs, despite raising over $5 million in fresh capital.

Emyria Limited has reported a significant 136% increase in revenue to $1.55 million for the half-year ended December 2025, driven by its expanding Empax clinic network and insurer-funded treatments across Australia. Despite this growth, the company posted a $2.37 million net loss, reflecting investments in scaling operations and infrastructure.

Tribeca Global Natural Resources Limited reported a remarkable turnaround with a $69.5 million net profit for the half-year ended December 2025, alongside a fully franked dividend declaration. The company’s net tangible asset per share more than doubled, reflecting strong commodity market dynamics and strategic investment execution.

Shriro Holdings reported solid half-year growth with revenue up 8.4% and NPAT rising 10%, underpinned by strong BBQ and kitchen appliance sales. The company reaffirmed its EBITDA guidance and announced a $15 million off-market share buy-back for FY26.

Metal Powder Works Limited reported a substantial increase in its half-year loss to $3.7 million, driven by investments in production scaling and market expansion. Revenue more than doubled, reflecting strong demand in defence, aerospace, and nuclear sectors.

Cryosite Limited reported a robust half-year with revenue up 25% and net profit rising 36%, driven by strong demand in temperature-controlled logistics and a strategic warehouse acquisition that doubles its storage capacity.

Aland Equity Group reported a sharp revenue decline and an 85% increase in losses for the half-year ending December 2025, while completing a major capital raise and reshuffling its board.

Biotron Limited reported a half-year loss as it completed the acquisition of Sedarex Limited and advanced its Hepatitis B drug candidate BIT-HBV001, backed by a $2.5 million capital raise. The company faces material uncertainty over its going concern status, hinging on securing further funding.

Dubber Corporation reported a 9% revenue decline to $18.7 million for the half-year ending December 2025, alongside a 65% reduction in net loss. The company pursues growth through AI innovation and cost efficiencies while navigating ongoing legal proceedings.

AVADA Group Limited reported an 11% revenue increase to $101.5 million in H1 FY26, driven by strong growth in Queensland and New South Wales and early gains from its business transformation. Despite a statutory loss, adjusted EBITDA improved, setting the stage for a stronger second half.

Jatcorp Limited reported a strong 36% revenue increase to $23 million for the half-year ended December 2025, narrowing its net loss and expanding its footprint across Asia Pacific markets despite ongoing legal challenges in China.